Evidence map›Paper›PMID 29653978›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018

Potential Impact of

Jeremie Calais, Amar U Kishan, Minsong Cao, Wolfgang P Fendler, Matthias Eiber, Ken Herrmann, Francesco Ceci, Robert E Reiter, Matthew B Rettig, John V Hegde and 5 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Incremental Impact of [Molecular imaging and biology · 2022
    Trial
  5. Prospective, Multisite, International Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Optimizing treatment for Gleason 10 prostate cancer: radiation dose escalation andStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. [Biomarker insights · 2025
    Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Jeremie CalaisAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Amar U KishanDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Minsong CaoDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Wolfgang P FendlerAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Matthias EiberAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Ken HerrmannAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Francesco CeciAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Robert E ReiterDepartment of Urology, UCLA, Los Angeles, California; and.
Matthew B RettigDepartment of Urology, UCLA, Los Angeles, California; and.
John V HegdeDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Narek ShaverdianDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Chris R KingDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Michael L SteinbergDepartment of Radiation Oncology, UCLA, Los Angeles, California.
Johannes CzerninAhmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Nicholas G NickolsDepartment of Radiation Oncology, UCLA, Los Angeles, California nnickols@mednet.ucla.edu.
University of California, Los Angeles · USEssen University Hospital · DE

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

Standard-of-care imaging for initial staging of prostate cancer (PCa) underestimates disease burden. Prostate-specific membrane antigen (PSMA) PET/CT detects PCa metastasis with superior accuracy, having a potential impact on the planning of definitive radiation therapy (RT) for nonmetastatic PCa. Our objectives were to determine how often definitive RT planning based on standard target volumes covers

Indexed as

OligopeptidesAgedAged, 80 and overCohort StudiesComputer SimulationEdetic AcidGallium IsotopesGallium RadioisotopesHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingPositron Emission Tomography Computed TomographyProspective StudiesProstateEdetic AcidGallium-68gallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesRadiopharmaceuticalsdefinitive radiotherapyinitial stagingPET/CTprostate cancerPSMA

Identifiers

PMID29653978
PMCPMC6225538
OpenAlexW2797344377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.